Ginkgo Bioworks Reports Q4 Loss of $107.53 Million

Ginkgo Bioworks sees a narrowed loss of $107.53M in Q4. Despite the continued losses, the company reported a revenue growth of 26.2%, which may signal potential recovery and interest for investors.

Date: 26-02-2025

AI Rating: 6

Earnings Per Share (EPS): Ginkgo Bioworks reported an EPS of -$2.00 for the fourth quarter, showing improvement compared to -$4.28 per share in the previous year. This narrowing of losses could be seen as a positive sign, although the company is still reporting a loss.

Revenue Growth: The company's revenue increased by 26.2%, reaching $43.85 million compared to $34.76 million last year. This growth in revenue despite the losses points towards an upward trajectory that could attract investor interest.

In summary, while Ginkgo Bioworks presents a loss in earnings, the improving EPS and significant revenue growth are factors that could influence investor sentiment and stock prices positively. Continued focus on revenue growth and cost management will be essential for future performance.

Stocks: DNA